AGC Biologics Announces Successful Completion of Production of Cancer-Specific Therapeutic Antibody Fragments with Var2 Pharmaceuticals
–News Direct– AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the companys two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment. The CDMOs work included information transfer and master cell bank creation, method implementation, pilot-scale evaluations, preparation for large-scale manufacturing, regulatory documentation support for EMA or FDA guidelines and product stability studies. "We prioritize unparalleled support for every project we undertake, ensuring
Read more